add directory ♦ physician position
Related Topics:
Antianxiety Agents :: Drugs and MedicationsAntidepressants :: Drugs and Medications
Antipsychotics :: Drugs and Medications
Stimulants :: Drugs and Medications
Today's News:
PubMed: 0278-5846
Chronic Pisa syndrome associated with switching antipsychotics from olanzapine to ziprasidone.
Yeh YW, Chen YC, Chen CK, Feng HM, Wang TY, Chen CL Related Articles Chronic Pisa syndrome associated with switching antipsychotics from olanzapine to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Nov 12; Authors: Yeh YW, Chen YC, Chen CK, Feng HM, Wang TY, Chen CL PMID: 19028541 [PubMed - as supplied by publisher]
Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis.
Rahimi R, Nikfar S, Abdollahi M Related Articles Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Nov 12; Authors: Rahimi R, Nikfar S, Abdollahi M Hypericum perforatum is a medicinal plant with established antidepressant properties. The aim of this meta-analysis was to compare the efficacy and tolerability of this antidepressant with selective serotonin reuptake inhibitors (SSRIs) as a group of standard antidepressants. For this purpose, Pubmed, Embase, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched for studies comparing efficacy and/or tolerability of Hypericum with SSRIs in the management of major depressive disorder (MDD). The search terms were: "Hypericum" or "St. John's wort" and "fluoxetine", "paroxetine", "citalopram", "serteraline", "escitalopram", or "fluvoxamine". Data were collected from 1966 to 2008 (up to June). "Clinical response", "remission", "mean reduction in Hamilton Rating Scale for Depression (HAMD) score from baseline", "total adverse events", and "withdrawals due to adverse events" were the key outcomes of interest. Thirteen randomized placebo controlled clinical trials met our criteria and were included. Comparison of SSRIs with placebo yielded a significant relative risk (RR) of 1.22 (95% confidence interval: 1.03-1.45, P=0.02) for clinical response (n=4), a non significant RR of 0.96 (95% CI: 0.71-1.29, P=0.76) for remission (n=4), and a significant effect size [weighted mean difference (wmd+)] of 1.33 (95% CI: 1.15-1.51, P<0.0001) for mean reduction in HAMD score from baseline (n=3). Comparison of Hypericum with SSRIs yielded a non significant relative risk (RR) of 0.99 (95% confidence interval: 0.91-1.08, P=0.83) for clinical response, a non significant RR of 1.1 (95% CI: 0.90-1.35, P=0.35) for remission, and a non-significant wmd+ of 0.32 (95% CI: -1.28-0.64, P=0.52) for mean reduction in HAMD score from baseline, a non significant RR of 0.85 (95% CI: 0.7-1.04, P=0.11) for any adverse events, and a significant RR of 0.53 (95% CI: 0.35-0.82, P=0.004) for withdrawals due to adverse events. Hypericum does not differ from SSRIs according to efficacy and adverse events in MDD. Lower withdrawal from study due to adverse events by Hypericum is an advantage in management of MDD. PMID: 19028540 [PubMed - as supplied by publisher]
Differences in cholesterol and metabolic syndrome between bipolar disorder men with and without suicide attempts.
Vuksan-Ćusa B, Marčinko D, Nađ S, Jakovljević M Related Articles Differences in cholesterol and metabolic syndrome between bipolar disorder men with and without suicide attempts. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Nov 12; Authors: Vuksan-Ćusa B, Marčinko D, Nađ S, Jakovljević M Patient with mental illnesses such as schizophrenia and bipolar disorder have an increased prevalence of metabolic syndrome (MetS) and its components compared to general population. Among psychiatric disorders, bipolar disorder ranks highest in suicidality with a relative risk ratio of completed suicide of about 25 compared to the general population. Regarding the biological hypotheses of suicidality, low blood cholesterol level has been extensively explored, although results are still conflicting. The aim of this study was to investigate whether there were differences in the serum cholesterol levels in hospitalized bipolar disorder men patients with history of suicide attempts (N=20) and without suicide attempts (N=20). Additionally, we investigated if there were differences in the prevalence of MetS according to NCEP ATP-III criteria in these two groups of patients. Results of the study indicated significantly lower serum cholesterol levels (p=0.013) and triglyceride levels (p=0.047), in the bipolar disorder men with suicide attempts in comparison to bipolar disorder men without suicide attempts. The overall prevalence of MetS was 11/40 (27.5%). On this particular sample it was higher in the non-attempters 8/20 (40.0%) than in attempters 3/20 (15.0%) bipolar men group, but without statistical significance. Lower concentrations of serum cholesterol might be useful biological markers of suicidality in men with bipolar disorder. PMID: 19026707 [PubMed - as supplied by publisher]
Subscribe to Psychopharmacology RSS feed 
Chronic Pisa syndrome associated with switching antipsychotics from olanzapine to ziprasidone.
Yeh YW, Chen YC, Chen CK, Feng HM, Wang TY, Chen CL Related Articles Chronic Pisa syndrome associated with switching antipsychotics from olanzapine to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Nov 12; Authors: Yeh YW, Chen YC, Chen CK, Feng HM, Wang TY, Chen CL PMID: 19028541 [PubMed - as supplied by publisher]
Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis.
Rahimi R, Nikfar S, Abdollahi M Related Articles Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Nov 12; Authors: Rahimi R, Nikfar S, Abdollahi M Hypericum perforatum is a medicinal plant with established antidepressant properties. The aim of this meta-analysis was to compare the efficacy and tolerability of this antidepressant with selective serotonin reuptake inhibitors (SSRIs) as a group of standard antidepressants. For this purpose, Pubmed, Embase, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched for studies comparing efficacy and/or tolerability of Hypericum with SSRIs in the management of major depressive disorder (MDD). The search terms were: "Hypericum" or "St. John's wort" and "fluoxetine", "paroxetine", "citalopram", "serteraline", "escitalopram", or "fluvoxamine". Data were collected from 1966 to 2008 (up to June). "Clinical response", "remission", "mean reduction in Hamilton Rating Scale for Depression (HAMD) score from baseline", "total adverse events", and "withdrawals due to adverse events" were the key outcomes of interest. Thirteen randomized placebo controlled clinical trials met our criteria and were included. Comparison of SSRIs with placebo yielded a significant relative risk (RR) of 1.22 (95% confidence interval: 1.03-1.45, P=0.02) for clinical response (n=4), a non significant RR of 0.96 (95% CI: 0.71-1.29, P=0.76) for remission (n=4), and a significant effect size [weighted mean difference (wmd+)] of 1.33 (95% CI: 1.15-1.51, P<0.0001) for mean reduction in HAMD score from baseline (n=3). Comparison of Hypericum with SSRIs yielded a non significant relative risk (RR) of 0.99 (95% confidence interval: 0.91-1.08, P=0.83) for clinical response, a non significant RR of 1.1 (95% CI: 0.90-1.35, P=0.35) for remission, and a non-significant wmd+ of 0.32 (95% CI: -1.28-0.64, P=0.52) for mean reduction in HAMD score from baseline, a non significant RR of 0.85 (95% CI: 0.7-1.04, P=0.11) for any adverse events, and a significant RR of 0.53 (95% CI: 0.35-0.82, P=0.004) for withdrawals due to adverse events. Hypericum does not differ from SSRIs according to efficacy and adverse events in MDD. Lower withdrawal from study due to adverse events by Hypericum is an advantage in management of MDD. PMID: 19028540 [PubMed - as supplied by publisher]
Differences in cholesterol and metabolic syndrome between bipolar disorder men with and without suicide attempts.
Vuksan-Ćusa B, Marčinko D, Nađ S, Jakovljević M Related Articles Differences in cholesterol and metabolic syndrome between bipolar disorder men with and without suicide attempts. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Nov 12; Authors: Vuksan-Ćusa B, Marčinko D, Nađ S, Jakovljević M Patient with mental illnesses such as schizophrenia and bipolar disorder have an increased prevalence of metabolic syndrome (MetS) and its components compared to general population. Among psychiatric disorders, bipolar disorder ranks highest in suicidality with a relative risk ratio of completed suicide of about 25 compared to the general population. Regarding the biological hypotheses of suicidality, low blood cholesterol level has been extensively explored, although results are still conflicting. The aim of this study was to investigate whether there were differences in the serum cholesterol levels in hospitalized bipolar disorder men patients with history of suicide attempts (N=20) and without suicide attempts (N=20). Additionally, we investigated if there were differences in the prevalence of MetS according to NCEP ATP-III criteria in these two groups of patients. Results of the study indicated significantly lower serum cholesterol levels (p=0.013) and triglyceride levels (p=0.047), in the bipolar disorder men with suicide attempts in comparison to bipolar disorder men without suicide attempts. The overall prevalence of MetS was 11/40 (27.5%). On this particular sample it was higher in the non-attempters 8/20 (40.0%) than in attempters 3/20 (15.0%) bipolar men group, but without statistical significance. Lower concentrations of serum cholesterol might be useful biological markers of suicidality in men with bipolar disorder. PMID: 19026707 [PubMed - as supplied by publisher]
Sites:
4therapy.com - Psychiatric Medications: Find the best drug rehabilitation treatment centers, psychologists, therapist and eating disorder treatment centers. Also featuring rapid detox, drug addiction programs suited to yourur specific needs.A Reevaluation of the Relationship Between Psychiatric Diagnosis and Chemical Imbalances: An article about the relationship between psychiatric diagnosis and chemical imbalances
APA Division of Psychopharmacology and Substance Abuse: The APA's page dedicated to drugs, medication and substance abuse. An online newsletter, public policy advisories, action alerts, web resources.
APA Psychiatric Medications Overview: All about psychiatric medications. Mental Health communities for people with psychiatric disorders, their families, friends. Expert information, mental health support groups, chat, journals, buddy lists.
Atlantic Psychopharmacology Quarterly: Journal on psychiatric medication. The first issue is free and available online.
Basic Psychopharmacology of Antidepressants: how do antidepressants work?
Crazy Meds - Mental Illness With an Attitude: A guide to psychiatric medications from first-hand experience, anecdotal evidence and personal research.
Depression Drugs Blog: The effects of various antidepressant drugs.
Drug Therapy of Mood Disorders: A authoritative compendium of information on all aspects of psychopharmacology and drug treatment for people with mood disorders.
Drugs, Brains and Behavior: Drugs, Brains and Behavior, a textbook of behavioral pharmacology by C. R. Timmons and L. W. Hamilton, is freely available in its entirety at http://www.rci.rutgers.edu/~lwh/drugs/ and at http://www.users.drew.edu/ctimmons/drugs/.
HealthyPlace Psychiatric Medications: Psychiatric medications pharmacology. Usage, dosage, side effects of psychiatric medications including antidepressants, antipsychotics, antianxiety medications.
Neuropsychopharmacology: The Fifth Generation of Progress Online: Online book about the latest developments in neuropsychopharmacology by the American College of Neuropsychopharmacology.
Pacific Neuropsychiatric Institute: Psychopharmacology: The Pacific Neuropsychiatric Institute (PNI) is involved with comprehensive evaluation and management in Neuropsychiatry and Psychopharmacology at the clinical, research, forensic, education and phenomenologic levels.
Pioneer Pharmaceutical Research: Pioneer Behavioral Health is to help people gain and maintain physical, spiritual and emotional health. Pioneer Healthcare does so by developing and delivering the highest quality, most culturally responsive, compassionate and competitive services to individuals, corporations and identified commu...
Project MED: Project MED booklets - table of contents of psychopharmacological medication guides.
Psychiatric Drug Facts: Peter R. Breggin MD, psychiatrist, author and medical expert provides up to date information on psychiatric drugs, adverse drug effects, and recent criminal, malpractice, and product liability cases.
Psychopharmacology Links: Links to information on specific psychiatric medications. balanced perspective, no ads, not affiliated with pharmaceutical companies
Psychopharmacology Tips: These tips are just that -- tips -- and not (with some exceptions) the results of scientific studies. They should not be construed as providing diagnosis, medical advice, or treatment.
Psychopharmacology Update Notes: Analyses of the comparative effectiveness, side effects and toxicity of psychotropic drugs with emphases on serotonin syndrome and monoamine oxidase inhibitors.
PsychopharmINFO: Daily and monthly updates of Medline research articles about psychiatric medications, mostly antidepressants.
Stimulant Plants: Brief definition of neuropharmacology and psychopharmacology and surveys of the most commonly used drugs that originate as stimulant plants.
The Good Drug Guide: What's the best way to abolish mental pain?
The Neuropsychopharmacology of Personality Disorders: Article regarding the neuropsychopharmacology of personality disorders.
Virtual Hospital: Clinical Psychopharmacology Seminar: Virtual Hospital was a digital library of health information in pediatrics, paediatrics, and radiology for pediatric education and radiology education
This directory is based on the Open Directory and may have been modified